Larimar Therapeutics Inc (LRMR)
9.39
-0.30
(-3.10%)
USD |
NASDAQ |
Jun 14, 16:00
9.38
-0.01
(-0.11%)
After-Hours: 20:00
Larimar Therapeutics Research and Development Expense (Annual): 27.67M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 27.67M |
| December 31, 2022 | 24.25M |
| December 31, 2021 | 38.40M |
| Date | Value |
|---|---|
| December 31, 2020 | 31.41M |
| December 31, 2019 | 20.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
20.79M
Minimum
2019
38.40M
Maximum
2021
28.50M
Average
27.67M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Biogen Inc | 2.462B |
| Eli Lilly and Co | 9.313B |
| PTC Therapeutics Inc | 666.56M |
| Design Therapeutics Inc | 57.06M |
| CEL-SCI Corp | 22.47M |